Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Aravive (ARAV – Research Report), Prelude Therapeutics (PRLD – Research Report) and Mineralys Therapeutics, Inc. (MLYS – Research Report).
Aravive (ARAV)
In a report released today, Robert Hazlett from BTIG maintained a Buy rating on Aravive, with a price target of $12.00. The company’s shares closed last Wednesday at $1.61.
According to TipRanks.com, Hazlett is a 1-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Aravive with a $13.00 average price target, which is a 683.1% upside from current levels. In a report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $12.00 price target.
See today’s best-performing stocks on TipRanks >>
Prelude Therapeutics (PRLD)
Morgan Stanley analyst Jeffrey Hung maintained a Hold rating on Prelude Therapeutics yesterday and set a price target of $10.00. The company’s shares closed last Wednesday at $6.52.
According to TipRanks.com, Hung is a 5-star analyst with an average return of
Prelude Therapeutics has an analyst consensus of Hold, with a price target consensus of $10.00.
Mineralys Therapeutics, Inc. (MLYS)
Bank of America Securities analyst Greg Harrison reiterated a Buy rating on Mineralys Therapeutics, Inc. yesterday and set a price target of $39.00. The company’s shares closed last Wednesday at $16.35.
According to TipRanks.com, Harrison is a 3-star analyst with an average return of
Currently, the analyst consensus on Mineralys Therapeutics, Inc. is a Strong Buy with an average price target of $36.60, a 121.4% upside from current levels. In a report issued on March 7, Stifel Nicolaus also initiated coverage with a Buy rating on the stock with a $45.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ARAV:
- Aravive Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates
- Aravive receives orphan drug designation for batiraxcept from FDA
- 2 “Strong Buy” Penny Stocks With Multibagger Potential
- Aravive’s batiraxcept granted orphan designation in pancreatic cancer treatment
- Aravive to Present Positive Updated Data from Phase 1b Trial of Batiraxcept in Combination with Cabozantinib for Treatment of Clear Cell Renal Cell Carcinoma at the 2023 ASCO Genitourinary (GU) Cancers Symposium
